Athena Appeal Decision Could Open ‘Floodgate’ For False Claims Litigation
This article was originally published in The Tan Sheet
Lower court decisions that Athena Cosmetics’ RevitaLash products is an unapproved drug competing unfairly against Allergan's Latisse drug could have broader implications if the Supreme Court denies the firm's request for review. Already beleaguered by class actions following FDA warnings, firms could face more opportunistic lawsuits if federal courts are left to determine a product's intended use and regulatory status.
Register for our free email digests: